Single- and Repeat-dose Oral Toxicity Studies of Lithospermum erythrorhizon Extract in Dogs
Authors:
Open Access
- 31 March 2015
- journal article
- Published by Springer Nature in Toxicological Research
- Vol. 31 (1) , 77-88
Abstract
Lithospermum erythrorhizon has long been used in traditional Asian medicine for the treatment of diseases, including skin cancer. The oral toxicity of a hexane extract of Lithospermum erythrorhizon root (LEH) was investigated in Beagle dogs by using single escalating doses, two-week dose range-finding, and 4-week oral repeat dosing. In the single dose-escalating oral toxicity study, no animal died, showed adverse clinical signs, or changes in body weight gain at LEH doses of up to 2,000 mg/kg. In a 2 week dose range-finding study, no treatment-related adverse effects were detected by urinalysis, hematology, blood biochemistry, organ weights, or gross and histopathological examinations at doses of up to 500 mg LEH/kg/day. In the 4 week repeat-dose toxicity study, a weight loss or decreased weight gain was observed at 300 mg/kg/day. Although levels of serum triglyceride and total bilirubin were increased in a dose dependent manner, there were no related morphological changes. Based on these findings, the sub-acute no observable adverse effect level for 4-week oral administration of LEH in Beagles was 100 mg/kg/day.Keywords
This publication has 12 references indexed in Scilit:
- Shikonin promotes intestinal wound healing in vitro via induction of TGF-β release in IEC-18 cellsEuropean Journal of Pharmaceutical Sciences, 2013
- In vitro and in vivo anticancer effects of Lithospermum erythrorhizon extract on B16F10 murine melanomaJournal of Ethnopharmacology, 2012
- Evaluation of the effectiveness of an ointment based on Alkannins/Shikonins on second intention wound healing in the dog.2011
- Shikonin inhibits the proliferation and induces the apoptosis of human HepG2 cellsCanadian Journal of Physiology and Pharmacology, 2010
- Shikonin inhibits maturation of bone marrow‐derived dendritic cells and suppresses allergic airway inflammation in a murine model of asthmaBritish Journal of Pharmacology, 2010
- Shikonin Induces Apoptosis through Reactive Oxygen Species/Extracellular Signal-Regulated Kinase Pathway in Osteosarcoma CellsBiological and Pharmaceutical Bulletin, 2010
- Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivoInternational Journal of Cancer, 2009
- Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cellsCell Research, 2008
- Growth inhibition and induction of apoptosis in human oral squamous cell carcinoma Tca‐8113 cell lines by shikonin was partly through the inactivation of NF‐κB pathwayPhytotherapy Research, 2007
- Cellular pharmacology studies of shikonin derivativesPhytotherapy Research, 2002